A Systematic Review of the Role of Monoclonal Antibodies as CGRP Inhibitors in Preventing Chronic and Episodic Migraine.

Migraine is a common and debilitating neurological condition affecting many people. Current treatments often do not provide sufficient relief or cause unwanted side effects. Researchers have focused on Calcitonin Gene-Related Peptide (CGRP) and its role in migraines. Monoclonal antibodies targeting CGRP or its receptors have been developed to help. This systematic review analyzes how effective these antibodies are for migraine prevention. The review follows strict guidelines to ensure thoroughness and reliability. It examines studies on adults with chronic or episodic migraines. The findings suggest that these monoclonal antibodies can significantly reduce migraine frequency and severity. They also report improved safety profiles compared to traditional treatments. Overall, this research highlights the potential of CGRP inhibitors to enhance migraine management and improve patients' quality of life. Future treatments may become more targeted, leading to better outcomes for migraine sufferers everywhere. Clinical relevance: This research indicates that CGRP-targeting monoclonal antibodies may significantly improve migraine treatment outcomes for patients.